Meeting
2022 ASCO Gastrointestinal Cancers Symposium
The prevalence of common KRAS variants and associated outcomes in patients with metastatic colorectal cancer (mCRC).
Authors
Laura W. Musselwhite
Levine Cancer Institute, Charlotte, NC
Laura W. Musselwhite , Sally J. Trufan , Kunal C. Kadakia , Jimmy J. Hwang , Mohamed E. Salem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
DOI
10.1200/JCO.2022.40.4_suppl.173
Abstract #
173
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Tumor bulk as a prognostic biomarker and predictor of benefit from anti-EGFR therapy in patients with metastatic colorectal cancer: Analysis of 476 patients from the ARCAD Clinical Trials Program.
First Author: Benjamin Adam Weinberg
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Impact of KRAS mutation variants on clinicopathological features and outcomes in patients with metastatic pancreatic adenocarcinoma.
First Author: Chirag Patel
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS G12C–mutated metastatic colorectal cancer in AACR Project GENIE.
First Author: Hil Hsu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer (mCRC).
First Author: Tsung-Che Wu